FAXDC2 is a cholesterol biosynthesis enzyme that functions as a C4 methyl sterol oxidase in the Kandutsch-Russell pathway 1. Beyond its enzymatic role, FAXDC2 promotes megakaryocyte differentiation through ERK phosphorylation and RUNX1 upregulation. In cancer biology, FAXDC2 exhibits tumor-suppressive functions. It inhibits hepatocellular carcinoma proliferation and invasion by suppressing ERK phosphorylation and upregulating E-cadherin, with decreased FAXDC2 expression correlating to poor prognosis 2. FAXDC2 links Wnt/β-catenin signaling to RTK/MAPK pathways; Wnt inhibition increases RTK recycling and MAPK activation through FAXDC2-dependent mechanisms 1. FAXDC2 is repressed in Wnt-high cancers and colorectal malignancies, where accumulation of its substrate lophenol marks cancerous tissue 1. Clinically, FAXDC2 is incorporated into cholesterol-related prognostic signatures for head and neck squamous cell carcinoma 3, and appears as a component of Sorafenib-response regulatory networks in hepatocellular carcinoma 4. The gene also associates with ferroptosis-related iron metabolism alterations in UVB-induced melanocyte damage 5. These findings position FAXDC2 as a critical integrator of lipid metabolism, developmental signaling, and cancer suppression.